 Connection
Elizabeth Kessler to Neoplasms
This is a "connection" page, showing publications Elizabeth Kessler has written about Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.463 |
|
|
|
-
Kessler ER, Moss A, Eckhardt SG, Laudenslager ML, Kilbourn K, Mauss IB, Bowles DW, Hecker S, Fairclough DL, Kutner JS. Distress among caregivers of phase I trial participants: a cross-sectional study. Support Care Cancer. 2014 Dec; 22(12):3331-40.
Score: 0.182
-
Carr AL, Bilenduke E, Adolf E, Kessler ER, Arch JJ, Ranby KW, Kilbourn K. A pilot randomized study of a telephone-based cognitive-behavioral stress-management intervention to reduce distress in phase 1 oncology trial caregivers. Palliat Support Care. 2023 Oct; 21(5):820-828.
Score: 0.086
-
Gilbert D, Hu J, Medina T, Kessler ER, Lam ET. Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors. Hum Vaccin Immunother. 2023 12 31; 19(1):2207438.
Score: 0.083
-
Dotan E, Walter LC, Browner IS, Clifton K, Cohen HJ, Extermann M, Gross C, Gupta S, Hollis G, Hubbard J, Jagsi R, Keating NL, Kessler E, Koll T, Korc-Grodzicki B, McKoy JM, Misra S, Moon D, O'Connor T, Owusu C, Rosko A, Russell M, Sedrak M, Siddiqui F, Stella A, Stirewalt DL, Subbiah IM, Tew WP, Williams GR, Hollinger L, George GV, Sundar H. NCCN Guidelines? Insights: Older Adult Oncology, Version 1.2021. J Natl Compr Canc Netw. 2021 09 20; 19(9):1006-1019.
Score: 0.074
-
Bowles DW, Kessler ER, Jimeno A. Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib). Drugs Today (Barc). 2011 Nov; 47(11):857-68.
Score: 0.038
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|